Research Paper Volume 12, Issue 17 pp 17380—17392
Identification of a cullin5-RING E3 ligase transcriptome signature in glioblastoma multiforme
- 1 Nova Southeastern University, College of Osteopathic Medicine, Fort Lauderdale, FL 33134, USA
- 2 Zhejiang University, College of Pharmaceutical Science, Zhejiang Province 310027, PR China
- 3 Zhejiang Key Agricultural Enterprise Institute of Shouxiangu Rare Herb Product, Zhejiang Province 310027, PR China
Received: March 11, 2020 Accepted: July 7, 2020 Published: September 14, 2020https://doi.org/10.18632/aging.103737
How to Cite
Copyright: © 2020 Zheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Glioblastoma multiforme (GBM) is the deadliest type of brain tumor. The median survival time for patients with GBM is only 15 months, even following maximal surgical resection and chemotherapy and radiation therapy. A genetic biomarker could enable a paradigm shift in precise diagnosis, personalized therapeutics and prognosis. In this study, we employed the Chinese Glioma Genome Atlas, The Cancer Genome Atlas, and the Ivy Glioblastoma Atlas Project databases for RNA sequencing (RNA-seq) analysis and clinicopathological studies. We demonstrated that elevated expression of the RNF7, TCEB1, SOCS1 and SOCS3 genes, which encode components of cullin5-RING E3 ligase (CRL5), predict unfavorable GBM prognoses. In GBM and glioma cases carrying IDH1 mutations, SOCS1 and SOCS3 methylation was increased and their expression was downregulated. This study has thus identified a simple transcriptome signature for GBM prognosis.